The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects.
The aim of the study was to investigate the influence of the angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism on nonlipid effects of statins and fibrates in hypercholesterolemic subjects. C-reactive protein, homocysteine, adhesion molecules, CD40 ligand, interleukin-6 and monocyte chemoattractant protein-1 were measured prior to and following 30 days of simvastatin or fenofibrate therapy. Decreases in all the variables except for adhesion molecules and homocysteine were observed in both treatment groups, without genotype-related differences. Interestingly, fenofibrate treatment led to a significant increase in homocysteine levels (p = 0.03) only in carriers of the I allele. In conclusion, ACE genotype might help identify patients prone to this effect of fibrates.
Potaczek
Daniel P
DP
Department of Medicine, Jagellonian University School of Medicine, 8 Skawinska Str., 31-066 Cracow, Poland.
Undas
Anetta
A
Celinska-Lowenhoff
Magdalena
M
Szczeklik
Andrew
A
D000483:Alleles; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D005838:Genotype; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D019821:Simvastatin / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D006710:Homocysteine; D019821:Simvastatin; D007703:Peptidyl-Dipeptidase A; D011345:Fenofibrate